WO2000022124A3 - Methods and compositions to induce antitumor response - Google Patents

Methods and compositions to induce antitumor response Download PDF

Info

Publication number
WO2000022124A3
WO2000022124A3 PCT/US1999/021454 US9921454W WO0022124A3 WO 2000022124 A3 WO2000022124 A3 WO 2000022124A3 US 9921454 W US9921454 W US 9921454W WO 0022124 A3 WO0022124 A3 WO 0022124A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
cells
compositions
present invention
dendritic
induce
Prior art date
Application number
PCT/US1999/021454
Other languages
French (fr)
Other versions
WO2000022124A2 (en )
Inventor
Drake M Laface
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

(57) Abstract The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize, differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells). The present invention provides a method to induce an antitumor immune response through the use of such compositions.
PCT/US1999/021454 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response WO2000022124A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17320398 true 1998-10-15 1998-10-15
US09/173,203 1998-10-15

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU6497799A AU6497799A (en) 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response

Publications (2)

Publication Number Publication Date
WO2000022124A2 true WO2000022124A2 (en) 2000-04-20
WO2000022124A3 true true WO2000022124A3 (en) 2000-07-06

Family

ID=22630966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021454 WO2000022124A3 (en) 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response

Country Status (1)

Country Link
WO (1) WO2000022124A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
CA2439185A1 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constructs
CN105209054A (en) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIEU M-C ET AL.: "Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 2, 20 July 1998 (1998-07-20), pages 373 - 386, XP002133972 *
HE X-S ET AL.: "Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein", GENE, vol. 175, no. 1/2, 10 October 1996 (1996-10-10), pages 121 - 125, XP002041764 *
ISHIDA T ET AL.: "Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08-01), pages 244 - 251, XP000891464 *
SHERMAN L A ET AL.: "Strategies for tumor elimination by cytotoxic T lymphocytes", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 18, no. 1-2, 1998, pages 47 - 54, XP000877347 *
SONG W ET AL.: "Dendritic cells genetically modified with and adenovirus vector encoding the cDNA for a model antigen induce protective", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1247 - 1256, XP002133971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date Type
WO2000022124A2 (en) 2000-04-20 application

Similar Documents

Publication Publication Date Title
Le Bon et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
Yang et al. Induction of alloreactive cytotoxic T cells by acute virus infection of mice.
Ahlers et al. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge
Baxevanis et al. Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice
US7776344B2 (en) Methods related to immunostimulatory nucleic acid-induced interferon
WO2001022990A2 (en) Methods related to immunostimulatory nucleic acid-induced interferon
Regn et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
WO1995024485A3 (en) Coordinate in vivo gene expression
WO1998055495B1 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
Angénieux et al. Gene induction during differentiation of human monocytes into dendritic cells: an integrated study at the RNA and protein levels
Märten et al. Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activity of DCs
Trefilov et al. Strain Hardening and Fracture of Polycrystal Metals(Deformatsionnoe Uprochnenie i Razrushenie Polikrystallicheskikh Metallov)
Vos et al. Phenotypic and functional characterization of a panel of cytotoxic murine NK cell clones that are heterogeneous in their enhancement of Ig secretion in vitro.
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
Klostermann et al. Modification of the human allergic immune response by allergen-DNA–transfected dendritic cells in vitro
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
Schmidt et al. Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703
Osman et al. Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA
JPH03133382A (en) Tumor necrosis factor-alpha and-beta receptors
Schirrmacher et al. Biotherapy of cancer
US7078034B2 (en) In vitro activated γ δ lymphocytes
EP1688147A1 (en) Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
Van den Eynde Identification of cancer antigens of relevance for specific cancer immunotherapy

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 1999 64977

Kind code of ref document: A

Format of ref document f/p: F

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase